Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals Inc has experienced a significant downturn in financial performance, with revenue growth plummeting to -32.98% in Q3 2025 from +30.14% in Q2 2025. Profitability metrics are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback